Startups
At BioAI, we are developing world-leading machine learning technology to map the causal biology of disease, develop digital biomarkers, and identify novel drug targets, for the development of better medicine. BioAI’s PredictX Platform intakes your data and generates novel insights. PredictX is capable of ingesting a range of data types including: Digital Pathology, Multiomics, and Real-World Evidence. Using multimodal data and the most advanced AI methodologies, including In-silico phenotype projection and integrated deep learning, we can build predictive and prognostic models across a broad range of therapeutic areas. Founded by a group of friends who started by scribbling their ideas on a piece of paper, today we offer smart, innovative services to dozens of clients worldwide. Our team of experts has a proven track record in developing strategic partnerships with the Pharma industry and solving major challenges in R&D
Overview
Location
United States, New Hampshire, Manchester
Employees
11-50
Total raised
$500K
Founded date
2020
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 25, 2024 | BioAI and Genomic Testing Cooperative Partner on AI Pathology Solutions for Research and Diagnostics | BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider o... |
| Bio-AI Health | “We are committed to advancing Precision Medicine through the use of our AI to improve disease diagnosis and predict patient response to therapy.” |
Reviews 0
FAQ about BioAI
When was BioAI founded?
BioAI was founded in 2020.
How much funding has BioAI raised?
BioAI has raised $500K in total across 1 funding round.
What has the press written about BioAI?
Parsers VC has collected 3 articles mentioning BioAI, among them “BioAI and Genomic Testing Cooperative Partner on AI Pathology Solutions for Research and Diagnostics” (Jun 25, 2024) and “Bio-AI Health”.
Is BioAI still active?
Yes, BioAI is active; its latest activity on Parsers VC dates from Oct 9, 2024.